CONMED Shares Decline Following Strategic Withdrawal from Gastroenterology Portfolio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Should l Buy MEDP?
Source: NASDAQ.COM
CONMED's Strategic Shift: CONMED announced its exit from gastroenterology product lines, including an early termination of its distribution agreement with Gore for the VIABIL biliary stent, to focus on core areas like minimally invasive and orthopedic soft tissue surgery.
Financial Impact: The company expects a revenue loss of $90–$95 million from the gastroenterology segment in 2025 and anticipates earnings per share dilution of 45–55 cents in 2026, but aims to improve its gross margin profile by about 80 basis points in the long run.
Market Reaction: Following the announcement, CONMED's shares fell over 9%, reflecting investor concerns, as the company has seen a 41.5% decline in stock value year-to-date compared to industry growth.
Future Outlook: The exit is expected to streamline CONMED’s operations, enhance profitability, and allow for better resource allocation towards higher-growth potential areas, ultimately aiming for a more resilient business model.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 418.660
Low
462.00
Averages
569.17
High
660.00
Current: 418.660
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for failing to disclose the true conditions of Latin American patients, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with a lead plaintiff deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy & Digital (NASDAQ:NUAI) is being sued for overstating progress on its Texas data center project and involvement in fraudulent activities, with investors needing to file by June 1, 2026, facing risks of misleading financial results.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is accused of overselling its projected book-to-bill ratio for Q4 2025, with a lead plaintiff deadline of June 5, 2026, potentially indicating a weak business environment.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses in these companies to contact their firm to understand their legal rights and ensure protection in the class actions.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws during the period from April 22, 2025, to February 9, 2026, with a deadline to contact the firm by June 5, 2026.
- False Statement Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its share price, which resulted in investor losses once the truth was revealed, highlighting the company's misconduct in the market.
- Loss Recovery Opportunity: Affected shareholders are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and offering free legal consultations to help investors protect their rights.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially affecting their rights to claim damages.
See More
Medpace Faces Class Action Lawsuit Amid Stock Plunge
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Medpace Holdings, alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, with investors having until June 8, 2026, to apply as Lead Plaintiff.
- Earnings Miss: On February 9, 2026, Medpace reported a fourth-quarter 2025 book-to-bill ratio of 1.04, significantly below the company's guidance, leading to diminished market confidence in its future performance.
- Stock Price Plunge: Following the disappointing earnings report, Medpace's stock price fell by $84.30, or 15.9%, closing at $446.05 on February 10, 2026, indicating investor concerns about the company's outlook.
- Legal Background: Pomerantz LLP is a prominent law firm specializing in class action litigation in securities and antitrust, with a long history of recovering multimillion-dollar damages for victims, underscoring its strong position in the legal field.
See More
Reminder for Medpace Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace securities between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiffs by June 8, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Medpace made false or misleading statements during the class period, concealing the true cancellation rates, which led investors to have overly optimistic expectations about the company's future growth, ultimately resulting in losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and successful track record in this field.
See More
Faruqi & Faruqi Investigates Investor Losses in Medpace Securities
- Legal Investigation Launched: Faruqi & Faruqi, LLP is investigating Medpace Holdings, Inc. for potential claims related to investor losses incurred between April 22, 2025, and February 9, 2026, which may expose the company to legal liabilities.
- Investor Rights Reminder: The firm reminds investors that June 8, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, indicating potential risks of collective litigation against the company.
- Direct Contact Channels: Investors who have suffered losses are encouraged to contact Faruqi & Faruqi partner Josh Wilson directly, with multiple contact numbers provided to facilitate consultations for affected investors.
- Potential Claim Opportunities: This investigation may offer avenues for compensation to affected investors, highlighting the law firm's commitment to protecting investor rights, which could also impact Medpace's market reputation.
See More
Medpace Accused of Misleading Investors on Book-to-Bill Ratio
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased Medpace Holdings Inc. (NASDAQ:MEDP) securities between April 22, 2025, and February 9, 2026, highlighting concerns over the company's financial transparency.
- False Expectations Allegations: The lawsuit alleges that Medpace misled investors by continuously claiming a book-to-bill ratio of 1.15 for the second half of fiscal year 2025 during earnings calls, while the actual fourth-quarter ratio was only 1.04, indicating excessive optimism about future performance.
- Stock Price Volatility: Following the announcement of the disappointing book-to-bill ratio on February 9, 2026, Medpace's stock price plummeted from $530.35 to $446.05, a decline of over 15.9%, reflecting market disappointment regarding the company's financial health.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by June 8, 2026, emphasizing the importance of corporate governance and transparency to investors.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for failing to disclose the true conditions of Latin American patients, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with a lead plaintiff deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy & Digital (NASDAQ:NUAI) is being sued for overstating progress on its Texas data center project and involvement in fraudulent activities, with investors needing to file by June 1, 2026, facing risks of misleading financial results.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is accused of overselling its projected book-to-bill ratio for Q4 2025, with a lead plaintiff deadline of June 5, 2026, potentially indicating a weak business environment.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses in these companies to contact their firm to understand their legal rights and ensure protection in the class actions.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws during the period from April 22, 2025, to February 9, 2026, with a deadline to contact the firm by June 5, 2026.
- False Statement Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its share price, which resulted in investor losses once the truth was revealed, highlighting the company's misconduct in the market.
- Loss Recovery Opportunity: Affected shareholders are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and offering free legal consultations to help investors protect their rights.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially affecting their rights to claim damages.
See More
Medpace Faces Class Action Lawsuit Amid Stock Plunge
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Medpace Holdings, alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, with investors having until June 8, 2026, to apply as Lead Plaintiff.
- Earnings Miss: On February 9, 2026, Medpace reported a fourth-quarter 2025 book-to-bill ratio of 1.04, significantly below the company's guidance, leading to diminished market confidence in its future performance.
- Stock Price Plunge: Following the disappointing earnings report, Medpace's stock price fell by $84.30, or 15.9%, closing at $446.05 on February 10, 2026, indicating investor concerns about the company's outlook.
- Legal Background: Pomerantz LLP is a prominent law firm specializing in class action litigation in securities and antitrust, with a long history of recovering multimillion-dollar damages for victims, underscoring its strong position in the legal field.
See More
Reminder for Medpace Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace securities between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiffs by June 8, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Medpace made false or misleading statements during the class period, concealing the true cancellation rates, which led investors to have overly optimistic expectations about the company's future growth, ultimately resulting in losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and successful track record in this field.
See More
Faruqi & Faruqi Investigates Investor Losses in Medpace Securities
- Legal Investigation Launched: Faruqi & Faruqi, LLP is investigating Medpace Holdings, Inc. for potential claims related to investor losses incurred between April 22, 2025, and February 9, 2026, which may expose the company to legal liabilities.
- Investor Rights Reminder: The firm reminds investors that June 8, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, indicating potential risks of collective litigation against the company.
- Direct Contact Channels: Investors who have suffered losses are encouraged to contact Faruqi & Faruqi partner Josh Wilson directly, with multiple contact numbers provided to facilitate consultations for affected investors.
- Potential Claim Opportunities: This investigation may offer avenues for compensation to affected investors, highlighting the law firm's commitment to protecting investor rights, which could also impact Medpace's market reputation.
See More
Medpace Accused of Misleading Investors on Book-to-Bill Ratio
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased Medpace Holdings Inc. (NASDAQ:MEDP) securities between April 22, 2025, and February 9, 2026, highlighting concerns over the company's financial transparency.
- False Expectations Allegations: The lawsuit alleges that Medpace misled investors by continuously claiming a book-to-bill ratio of 1.15 for the second half of fiscal year 2025 during earnings calls, while the actual fourth-quarter ratio was only 1.04, indicating excessive optimism about future performance.
- Stock Price Volatility: Following the announcement of the disappointing book-to-bill ratio on February 9, 2026, Medpace's stock price plummeted from $530.35 to $446.05, a decline of over 15.9%, reflecting market disappointment regarding the company's financial health.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by June 8, 2026, emphasizing the importance of corporate governance and transparency to investors.
See More
